Merck impresses NICE with Keytruda data—and discounts—cueing up a CDF switch

After making headlines at this year’s American Society of Clinical Oncology annual meeting, Merck’s Keytruda had a big week on the other side of the pond, too. On Wednesday, England’s cost-effectiveness gatekeepers at the National Institute for Health and Care Excellence recommended the drug in draft guidance for routine use as a treatment for previously untreated lung cancer. https://www.fiercepharma.com/pharma/merck-impresses-nice-keytruda-data-and-discounts-cueing-up-a-cdf-switch